Aclaris Q3 net loss $20M, revenue $19M on $17.6M Lilly license; ATI-2138 Phase 1 SAD positive

Aclaris Therapeutics, Inc.

2022-Q3 EPS reported -$0.92 revenue$21,999,000

Net loss of $20.0M for Q3 2022 vs $21.1M in Q3 2021; operating loss offset by $17.6M licensing revenue from Lilly alopecia areata patent deal.
Total revenue of $19.0M, up from $1.7M year-over-year, driven by $17.9M licensing revenue.
Cash, equivalents and marketable securities of $248.1M as of Sep 30, 2022; sufficient to fund operations through end of 2025.
Phase 2a enrollment completed for zunsemetinib in hidradenitis suppurativa (95 patients); topline data expected mid-first half 2023.
ATI-2138 Phase 1 SAD trial completed; generally well-tolerated, dose-dependent ITK/JAK3 inhibition; ulcerative colitis selected as first target; new IND submitted.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Aclaris Therapeutics, Inc. reported financial results for the quarter and nine months ended September 30, 2022.

Period: the quarter and nine months ended September 30, 2022
Result: reported results

Exact text from the filing

On November 8, 2022, Aclaris Therapeutics, Inc. (the “ Registrant ”) issued a press release announcing its financial results for the quarter and nine months ended September 30, 2022

View on SEC.gov

Browse all earnings releases →

Aclaris Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-22-016735

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.